ARL5B

Across TCGA pan-cancer cohorts, ARL5B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARL5B data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARL5B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARL5B expression acts as an unfavorable survival marker, although some lineages such as UCEC and HNSC show a favorable association.

UCEC, PDAC, and HNSC are the cancer types where ARL5B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	II,III,IV	0.908	0.390	.011	30	view →
PDAC	DFS	Median	IV	0.235	0.934	.024	6	view →
HNSC	DFS	Quartile	All	0.860	0.627	.008	3	view →
LUAD	DFS	Tertile	All	0.694	0.853	.031	3	view →
CCRCC	DFS	Median	All	0.339	0.805	.048	2	view →
LSCC	OS	Median	II,III,IV	1.000	0.833	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARL5B–UCEC (DFS)

Open the UCEC breakdown →